Mydecine Innovations Group (OTCMKTS:MYCOF) Trading 0.2% Higher – What’s Next?
by Michael Walen · The Markets DailyShares of Mydecine Innovations Group Inc. (OTCMKTS:MYCOF – Get Free Report) were up 0.2% on Tuesday . The company traded as high as $1.32 and last traded at $1.32. Approximately 388 shares changed hands during trading, a decline of 83% from the average daily volume of 2,318 shares. The stock had previously closed at $1.3175.
Mydecine Innovations Group Price Performance
The stock’s 50 day moving average price is $0.78 and its two-hundred day moving average price is $0.35.
Mydecine Innovations Group Company Profile
Mydecine Innovations Group (OTCMKTS:MYCOF) is a clinical‐stage biotechnology company dedicated to the research, development and commercialization of novel therapeutics derived from psychedelic and plant-based compounds. The company’s primary focus lies in advancing a pipeline of next‐generation product candidates targeting mental health disorders, addiction and other neurological conditions. Mydecine holds a portfolio of intellectual property that encompasses proprietary chemical entities, drug delivery systems and manufacturing processes for molecules such as 5-MeO-DMT analogs, ibogaine-derived compounds and psilocybin formulations.
Headquartered in Denver, Colorado, with additional research and manufacturing facilities in Vancouver, Canada, Mydecine operates a vertically integrated business model.